Reasons for delay in time to initiation of adjuvant chemotherapy (TTAC) for colon cancer (CC): Analysis from six academic centers in Ontario, Canada.

Authors

null

Ketan Ghate

Queen's University/Cancer Centre of SE Ontario, Kingston, ON, Canada

Ketan Ghate , Ronald L. Burkes , Christine B. Brezden , Kevin M. Zbuk , Brandon Matthew Meyers , Oren Hannun Levine , Silvana Spadafora , Stephen Welch , Yoo-Joung Ko , Sukaina Davdani , Wilma M Hopman , Christopher M. Booth , Rachel Anne Goodwin , James Joseph Biagi

Organizations

Queen's University/Cancer Centre of SE Ontario, Kingston, ON, Canada, Mount Sinai Hospital, Toronto, ON, Canada, St. Michael's Hospital, Toronto, ON, Canada, McMaster University Juravinski Cancer Center, Hamilton, ON, Canada, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada, McMaster Univ, Hamilton, ON, Canada, Group Health Centre and Algoma Regional Cancer Program, Sault Ste. Marie, ON, Canada, London Regional Cancer Program, London, ON, Canada, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, Department Public Health Sciences, Queen's University, Kingston, ON, Canada, Division of Cancer Care and Epidemiology, Cancer Research Institute, Queen's University, Kingston, ON, Canada, National Cancer Institute of Canada Clinical Trials Group, The Ottawa Hospital, Ottawa, ON, Canada, Cancer Centre of Southeastern Ontario, Kingston, ON, Canada

Research Funding

Other

Background: Adjuvant chemotherapy (AC) for CC has been shown to increase survival in randomized trials. Analysis of time from curative surgery to AC (TTAC) has demonstrated diminished survival with increasing TTAC. Few studies have examined the reasons underlying delays in TTAC. Methods: Data was extracted from individual medical records of 1159 patients with CC who initiated AC at six large academic centers in Ontario between 2005-2012, including patient demographics, disease characteristics, treatment, readmissions, length of hospital stay, post-operative complications and time intervals between each step from surgery to AC. Patients were categorized into three Groups: (I) postoperative surgical /medical complications, (II) oncologist or patient-initiated delay, (III) no delays. Groups were compared using X2 test and one-way analysis of variance. A multivariable logistic regression model was used to determine factors associated with TTAC > 8 weeks. Results: In this 1159 patient cohort, 54% were male, with 48% under 65 and 19% over 74 years of age. There were 21%, 18% and 60% in Groups I, II, III respectively. TTAC in the 3 Groups was (I) 9.9±2.9 weeks, (II) 10.2±3.6 weeks, (III) 8.8±2.7 weeks (P < 0.01). In multivariate analysis, advanced age, postoperative complications, oncologist- or patient-initiated delays and need for central line placement were significant predictors for TTAC > 8 weeks. In group III (n = 615), age (65-74 years) (OR = 1.54; 95% CI, 1.05-2.26) and central line (OR = 2.01; 95% CI, 1.27-3.17) were significant factors for TTAC > 8 weeks. In group III, 59% had TTAC > 8 weeks. In the overall cohort, 65% had TTAC > 8 weeks even though 92% were deemed fit for chemotherapy at the original consultation. Conclusions: In major academic centers in Ontario, the majority of patients receive AC more than 8 weeks after surgery, even though most patients had no identifiable medical or surgical reasons for delay. This is likely due to health-system factors such as delay in referrals, consultations, central line placement and chemotherapy bookings. Local and regional quality improvement initiatives are needed to improve health-system delays and decrease TTAC.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Health Services Research and Quality of Care

Track

Health Services Research and Quality of Care

Sub Track

Care Delivery/Models of Care

Citation

J Clin Oncol 34, 2016 (suppl; abstr 6541)

DOI

10.1200/JCO.2016.34.15_suppl.6541

Abstract #

6541

Poster Bd #

28

Abstract Disclosures

Similar Abstracts

First Author: Saurabh Parasramka

First Author: Eder Christian Veramendi Cabana

First Author: James Joseph Biagi

First Author: Jemma Megan Boyle